{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:05:30Z","timestamp":1789560330363,"version":"build-2803163510"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To describe the anti\u2013hepatitis B virus (HBV) efficacy, HBeAg serologic changes, HBV perinatal transmission, and safety in pregnant women who are living with human immunodeficiency virus (HIV) and HBV co-infection who were randomized to various antiretroviral therapy (ART) regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      The PROMISE (Promoting Maternal and Infant Survival Everywhere) trial was a multicenter randomized trial for ART-naive pregnant women with HIV infection. Women with HIV and HBV co-infection at 14 or more weeks of gestation were randomized to one of three ART arms: one without HBV treatment (group 1) and two HBV treatment arms with single (group 2) or dual anti-HBV activity (group 3). The primary HBV outcome was HBV viral load antepartum change from baseline (enrollment) to 8 weeks; safety assessments included alanine aminotransferase (ALT) level, aspartate aminotransferase (AST) level, and anemia (hemoglobin less than 10 g\/dL). Primary comparison was for the HBV-active treatment arms. Pairwise comparisons applied\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      test and the Fisher exact tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Of 3,543 women, 3.9% were HBsAg-positive; 42 were randomized to group 1, 48 to group 2, and 48 to group 3. Median gestational age at enrollment was 27 weeks. Among HBV-viremic women, mean antepartum HBV viral load change at week 8 was \u22120.26 log\n                      <jats:sub>10<\/jats:sub>\n                      international units\/mL in group 1, \u22121.86 in group 2, and \u22121.89 in group 3. In those who were HBeAg-positive, HBeAg loss occurred in 44.4% at delivery. Two perinatal HBV transmissions occurred in group 2. During the antepartum period, one woman (2.4%) in group 1 had grade 3 or 4 ALT or AST elevations, two women (4.2%) in group 2, and three women (6.3%) in group 3.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Over a short period of time, HBV DNA suppression was not different with one or two HBV-active agents. HbeAg loss occurred in a substantial proportion of participants. Perinatal transmission of HBV infection was low. Hepatitis B virus\u2013active ART was well-tolerated in pregnancy, with few grade 3 or 4 ALT or AST elevations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT01061151.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005302","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T18:37:17Z","timestamp":1691087837000},"page":"613-624","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Antiretroviral Therapies in Pregnant Women Living With Human Immunodeficiency Virus and Hepatitis B Virus"],"prefix":"10.1097","volume":"142","author":[{"given":"Debika","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camlin","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia Matovu","family":"Kiweewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhayendre","family":"Moodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani","family":"Govender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tichaona","family":"Vhembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neaka","family":"Mohtashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Ship","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingase","family":"Dula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahida","family":"Chaktoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Glenn","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith S.","family":"Currier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1016\/j.vaccine.2013.08.028","article-title":"The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa","volume":"31","author":"Andersson","year":"2013","journal-title":"Vaccine"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"e005889","DOI":"10.1136\/bmjopen-2014-005889","article-title":"High prevalence of hepatitis B virus infection among pregnant women attending antenatal care: a cross-sectional study in two hospitals in northern Uganda","volume":"4","author":"Bayo","year":"2014","journal-title":"BMJ Open"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2013.10.029","article-title":"Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants","volume":"60","author":"Chasela","year":"2014","journal-title":"J Hepatol"},{"key":"R4-20260916","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1471-2393-13-158","article-title":"Prevalence, correlates and pattern of hepatitis B among antenatal clinic attenders in Yaounde-Cameroon: is perinatal transmission of HBV neglected in Cameroon?","volume":"13","author":"Fomulu","year":"2013","journal-title":"BMC Pregnancy Childbirth"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jmv.20143","article-title":"HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, C\u00f4te d\u2019Ivoire: the ANRS 1236 study","volume":"74","author":"Rouet","year":"2004","journal-title":"J Med Virol"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/infdis\/jiw439","article-title":"Hepatitis B virus (HBV) load response to 2 antiviral regimens, tenofovir\/lamivudine and lamivudine, in HIV\/HBV-coinfected pregnant women in Guangxi, China: the tenofovir in pregnancy (TiP) study","volume":"214","author":"Wang","year":"2016","journal-title":"J Infect Dis"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"18871","DOI":"10.7448\/IAS.17.1.18871","article-title":"Maternal hepatitis B and infant infection among pregnant women living with HIV in South Africa","volume":"17","author":"Hoffmann","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jcv.2013.06.025","article-title":"Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring","volume":"58","author":"Khamduang","year":"2013","journal-title":"J Clin Virol"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/jvh.12301","article-title":"Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding","volume":"22","author":"Pirillo","year":"2015","journal-title":"J Viral Hepat"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1086\/593104","article-title":"Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program","volume":"47","author":"Hoffmann","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R11-20260916","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"New Engl J Med"},{"key":"R12-20260916","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1708131","article-title":"Tenofovir versus placebo to prevent perinatal transmission of hepatitis B","volume":"378","author":"Jourdain","year":"2018","journal-title":"New Engl J Med"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000001618","article-title":"HBV or HCV coinfection in HIV-1-Infected pregnant women in France: prevalence and pregnancy outcomes","volume":"77","author":"Benhammou","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/15284336.2016.1276312","article-title":"HBV coinfection is associated with reduced CD4 response to antiretroviral treatment in pregnancy","volume":"18","author":"Floridia","year":"2017","journal-title":"HIV Clin Trials"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MCG.0000000000000822","article-title":"Serum aminotransferase flares in pregnant and postpartum women with current or prior treatment for chronic hepatitis B","volume":"52","author":"Chang","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/apt.12726","article-title":"Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare","volume":"39","author":"Nguyen","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"R18-20260916","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","article-title":"Benefits and risks of antiretroviral therapy for perinatal HIV prevention","volume":"375","author":"Fowler","year":"2016","journal-title":"New Engl J Med"},{"key":"R28-20260916","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Babiker","year":"2015","journal-title":"New Engl J Med"},{"key":"R29-20260916","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/hep.22462","article-title":"A randomized trial of combination hepatitis B therapy in HIV\/HBV coinfected antiretroviral na\u00efve individuals in Thailand","volume":"48","author":"Matthews","year":"2008","journal-title":"Hepatology"},{"key":"R30-20260916","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/hep.22754","article-title":"Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1\u2013hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy","volume":"49","author":"Lewin","year":"2009","journal-title":"Hepatology"},{"key":"R31-20260916","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/01.aids.0000218550.85081.59","article-title":"Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy","volume":"20","author":"Matthews","year":"2006","journal-title":"AIDS"},{"key":"R32-20260916","first-page":"1","article-title":"Efficacy and safety of lamivudine or telbivudine in preventing mother-to-child transmission of hepatitis B virus: a real-world study","volume":"2020","author":"Li","year":"2020","journal-title":"BioMed Research International"},{"key":"R33-20260916","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2893.2008.01056.x","article-title":"Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study","volume":"16","author":"Xu","year":"2009","journal-title":"J Viral Hepat"},{"key":"R34-20260916","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/QAD.0000000000000686","article-title":"Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks","volume":"29","author":"Thio","year":"2015","journal-title":"AIDS"},{"key":"R35-20260916","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","article-title":"Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis","volume":"10","author":"M\u00fcller","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"R36-20260916","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/01.aids.0000131375.21070.06","article-title":"Immune restoration disease after antiretroviral therapy","volume":"18","author":"French","year":"2004","journal-title":"AIDS"},{"key":"R37-20260916","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12072-008-9063-4","article-title":"Chronic hepatitis B virus (HBV) infection in pregnancy","volume":"2","author":"Tan","year":"2008","journal-title":"Hepatol Int"},{"key":"R38-20260916","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/infdis\/jiz450","article-title":"High rates of hepatitis B virus (HBV) functional cure among human immunodeficiency virus-HBV coinfected patients on antiretroviral therapy in Zambia","volume":"221","author":"Chihota","year":"2019","journal-title":"J Infect Dis"},{"key":"R39-20260916","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","article-title":"HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment","volume":"31","author":"Singh","year":"2017","journal-title":"AIDS"},{"key":"R40-20260916","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1097\/QAD.0000000000000795","article-title":"Rates and determinants of hepatitis B \u2018e\u2019 antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus","volume":"29","author":"Boyd","year":"2015","journal-title":"AIDS"},{"key":"R41-20260916","doi-asserted-by":"crossref","first-page":"e0215464","DOI":"10.1371\/journal.pone.0215464","article-title":"Higher rates of HbsAg clearance with tenofovir-containing therapy in HBV\/HIV co-infection","volume":"14","author":"Gantner","year":"2019","journal-title":"PLoS One"},{"key":"R42-20260916","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/522173","article-title":"Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy","volume":"45","author":"Sheng","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R43-20260916","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1590\/s1518-8787.2017051006693","article-title":"Evolution of hepatitis B serological markers in HIV coinfected patients: a case study","volume":"51","author":"Toscano","year":"2017","journal-title":"Revista de Saude Publica"},{"key":"R44-20260916","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/jac\/dkh516","article-title":"Pharmacokinetics and hepatotoxicity of lopinavir\/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients","volume":"55","author":"Canta","year":"2005","journal-title":"J Antimicrob Chemother"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:05:30Z","timestamp":1789556730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005302"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005302","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"2022-10-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}